Evgen eyes an IPO do-over; Merck snags lung cancer nod for Keytruda;

@FierceBiotech: Spark soars on success of gene therapy study, shot at groundbreaking approval. Report | Follow @FierceBiotech

@JohnCFierce: That Shkreli scandal? Infecting Valeant and Mike Pearson as the industry runs away as fast as possible. New York Times article | Follow @JohnCFierce

> U.K. drugmaker Evgen is again planning to go public on the London exchange, looking to raise £5 million to support its pipeline. Earlier this year, the company nixed a move to raise £20 million through the same means. News

> Valeant Pharmaceuticals' ($VRX) drug pricing model has come under more scrutiny. More

> Merck's ($MRK) immuno-oncology treatment Keytruda won FDA approval to treat lung cancer, helping the company compete with a rival therapy from Bristol-Myers Squibb ($BMY). Story

Medical Device News

@FierceMedDev: ICYMI Friday: Investigational spinal cord implant bringing bodily sensation back to the lives of the paralyzed. Report | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: FTC weighs in on Mylan case, saying generics tweaking may be anticompetitive. Story | Follow @EmilyWFierce

> Boston Scientific wins $200M stent patent infringement case against doctor. Report

> Europe grants its first CE mark for leadless pacemaker to treat left ventricle. Article

Pharma News

@FiercePharma: ICYMI: Merck's Keytruda gets FDA approval for NSCLC ahead of BMS' Opdivo but label is limited. Article | Follow @FiercePharma

@EricPFierce: Swiss CMO Seigfried completes $302M deal for BASF API plants. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Ackman's fund takes a beating on Valeant pricing worries. Item | Follow @CarlyHFierce

> Last-minute deal on drug exclusivity wraps up TPP negotiations. Story

> Valeant's price-hike strategy goes far beyond two high-profile increases. Article

Animal Health News

> International health groups vow renewed effort to eradicate rabies. Report

> FDA seeks veterinarians' input on antibiotics resistance. Item

> USDA: Deadly pig virus likely carried into U.S. from China. More

> Stem cell treatment proves promising in dogs with Crohn's-like disease. Article

> WHO chief Margaret Chan vows to boost preparedness for disease outbreaks. Story

Biotech IT News

> Mount Sinai, Yale roll out updates to Apple ResearchKit programs. Report

> Allergan taps NuMedii's digital discovery platform for psoriasis R&D. News

> Illumina readies paid-for BaseSpace tiers for large organizations. More

> Cloud Pharmaceuticals, Therametrics hook up for CNS drug discovery drive. Story

> Berg to apply AI drug discovery model to U.K.'s genome data repository. Article

Pharma Marketing News

> BioMarin eyes SG&A efficiency on Kuvan; no worries on rare-disease pricing. Item

> Want to get a warning letter from OPDP? Omit drug risks from your promos. Story

> Teva snaps up Gecko and its 'smart inhaler' to pump up respiratory meds. More

> Veeva scoops up rival Zinc Ahead to create mega-content management platform. Report

> Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.